Netrin-1 Polypeptide Modulation for Sperm Concentration Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Male infertility issues, particularly low sperm count and quality, are prevalent due to hormonal imbalances, especially decreases in testosterone levels, and current hormone therapies have significant side effects.
Innovation Solution
The use of non-steroidal compositions and methods involving netrin-1, its agonists, antagonists, and derivatives to regulate spermiation and sperm concentration in males, including administering netrin-1 or its variants to increase sperm count or decrease sperm concentration as needed, and employing netrin-1 as a contraceptive to inhibit fertilization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If hormone therapies are used to treat male infertility, then testosterone levels can be increased, but serious side effects occur
Solution Approach 1:
The patent introduces netrin-1 as an intermediary substance that mediates spermiation and sperm concentration regulation without requiring direct testosterone supplementation. Netrin-1 acts as a signaling molecule that triggers endogenous sperm release mechanisms, thereby avoiding the side effects associated with exogenous hormone therapy while still achieving the desired increase in sperm concentration
Solution Approach 2:
The patent changes the therapeutic parameter from direct testosterone administration to netrin-1 administration. By altering the chemical parameter from steroid hormone to a different class of signaling molecule (netrin-1), the treatment achieves sperm concentration improvement through a different biological pathway that does not produce the harmful side effects of traditional hormone therapy
2Quantity of substance
If netrin-1 is administered to increase spermiation, then sperm concentration in semen increases, but the mechanism of action must be highly specific to avoid off-target effects
Solution Approach 1:
The patent employs netrin-1 variants with modified local properties - specifically, amino acid substitutions at positions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 that enhance binding affinity and specificity for sperm cell receptors. These localized modifications ensure that netrin-1 acts precisely on the target sperm cells without affecting other physiological systems
3Quantity of substance
If netrin-1 antagonists are used to decrease sperm concentration for contraception, then fertilization is prevented, but the composition must maintain stability and efficacy
Solution Approach 1:
The patent develops composite contraceptive compositions that combine netrin-1 antagonists with stabilizing excipients and delivery vehicles. These composite formulations protect the antagonist molecules from degradation, maintain their biological activity, and ensure consistent delivery to the target site, thereby solving the stability challenge while achieving the desired sperm concentration reduction
Data Source
AI summary
Methods and compositions for male or female contraception are provided. The compositions include an effective amount of netrin-1 to reduce or inhibit sperm concentration in semen of males or to inhibit or reduce fusion of male gametes with female gametes in a female subject Still another embodiment provides a method for diagnosing male infertility by determining the amount of netrin-1 in a sample of epididymal fluid or semen from a male subject, comparing the amount of netting-1 in the sample to levels of netrin-1 in samples of epididymal fluid or semen from fertile males, wherein levels of netrin-1 in the sample from the male subject that are higher or lower than levels of netrin-1 in samples from fertile males are indicative of male infertility in the male subject.